Table 3.
Logistic regression results examining predictors of HTE or subgroup analysis
| Predict HTE analysis | |
| Condition | OR (95% CI)* |
| Journal of publication | † |
| BMJ | 1.00 [reference] |
| Annals | 4.22 (1.18–15.08) |
| JAMA | 4.40 (1.43–13.53) |
| Lancet | 1.44 (0.55–3.77) |
| NEJM | 2.36 (0.85–6.56) |
| Year of publication | |
| 2004 | 1.00 [reference] |
| 1999 | 0.88 (0.47–1.66) |
| 1994 | 0.83 (0.41–1.67) |
| Medical condition under study | |
| Other | 1.00 [reference] |
| Cardiovascular | 1.07 (0.50–2.32) |
| Infectious disease | 1.38 (0.66–2.89) |
| Cancer | 1.13 (0.47–2.71) |
| Psychiatry/Neurology | 2.85 (0.91–8.92) |
| First author's study region | |
| Other | 1.00 [reference] |
| North America | 1.23 (0.67–2.29) |
| Sample size | ‡ |
| Quintile 1 (median = 37) | 1.00 [reference] |
| Quintile 2 (median = 124) | 0.72 (0.24–2.14) |
| Quintile 3 (median = 263) | 4.17 (1.62–10.74) |
| Quintile 4 (median = 549) | 3.08 (1.20–7.91) |
| Quintile 5 (median = 1560) | 7.55 (2.95–19.33) |
Abbreviations: HTE, heterogeneity of treatment effects; OR, odds ratio; CI, confidence interval; BMJ, British Medical Journal; JAMA, Journal of the American Medical Association; NEJM, New England Journal of Medicine
*Adjusted for all other variables in the model
†Significant at p < 0.05 for a combined Wald Chi-square test
‡Significant at p < 0.001 for a combined Wald Chi-square test